With Brain Scan Volume Momentum Accelerating, Firefly Makes History by Building the World’s First Known 200,000+ Standardized EEG/ERP Depository
Rhea-AI Summary
Firefly (NASDAQ: AIFF) announced it has surpassed 200,000 standardized EEG/ERP brain scans, driven by organic growth and the May 2025 acquisition of Evoke Neuroscience. Sequential scan volumes grew 5%, 11%, 15%, and 17% in the last four quarters, and the company cites NVIDIA L40S GPU acceleration to boost AI biomarker discovery.
This milestone supports Firefly’s stated goal of building and launching the world’s first EEG/ERP-based foundation model of the human brain.
Positive
- 200,000+ standardized EEG/ERP scans reached
- Sequential volume acceleration: 5%, 11%, 15%, 17% over four quarters
- May 2025 acquisition of Evoke Neuroscience expanded data base
- NVIDIA L40S GPU acceleration for faster EEG/ERP processing
Negative
- None.
News Market Reaction – AIFF
On the day this news was published, AIFF gained 6.00%, reflecting a notable positive market reaction. Argus tracked a peak move of +9.9% during that session. Argus tracked a trough of -4.4% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $23.52M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AIFF is down 12.28% while peers show mixed momentum: two up (e.g., NTCL +5.39%) and two down (e.g., WETO -4.01%, BMR -3.89%). Scanner data flags a broader sector move rather than a purely isolated reaction.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | Government partnership | Positive | +79.8% | Public-private PTSD/TBI partnership expanding into defense and veterans’ health. |
| Mar 13 | Biomarker discovery | Positive | +58.0% | New ADHD brain wave biomarkers using FDA 510(k)-cleared Evoke platform. |
| Mar 4 | Platform expansion | Positive | +126.3% | Reported 20x+ footprint, 33x scan growth, and NVIDIA GPU–powered model progress. |
| Nov 12 | Earnings update | Positive | +5.5% | Q3 2025 revenue growth, higher scan volumes, and lower operating expenses. |
Recent positive operational and partnership news has typically seen strong upside price reactions, contrasting with today’s negative move on another growth milestone.
Over the past six months, Firefly has repeatedly highlighted rapid EEG/ERP scaling and AI progress. On Mar 4, 2026, it reported a >20-fold commercial footprint expansion and 33-fold scan increase, which saw a 126.28% move. Subsequent ADHD biomarker discovery on Mar 13, 2026 and a government PTSD/TBI partnership on Mar 26, 2026 also drew strong gains. Today’s 200,000+ scan milestone extends that data-growth narrative but comes alongside a sharp pre-news price pullback.
Regulatory & Risk Context
An effective mixed Form S-3 shelf filed on Dec 3, 2025 registers up to $250,000,000 of securities, giving Firefly flexibility to issue equity, debt, or other securities over time. One usage is already reflected via a $7,434,266 at-the-market program, indicating an established path for future capital raises that could impact existing shareholders.
Market Pulse Summary
The stock moved +6.0% in the session following this news. A strong positive reaction aligns with Firefly’s pattern of outsized moves on data and AI milestones, as seen after prior EEG/ERP and partnership announcements with gains up to 126.28%. The 200,000+ scan milestone further deepens its dataset for brain-focused AI models. However, investors would need to weigh this enthusiasm against the company’s existing $250,000,000 shelf capacity and prior at-the-market usage, which allow additional capital raises.
Key Terms
eeg/erp medical
nvidia l40s gpu technical
biomarker medical
adhd medical
dementia medical
alzheimer's medical
foundation model technical
AI-generated analysis. Not financial advice.
- Firefly’s total brain scan volumes have increased sequentially by higher percentages in each of the past four quarters -
- Firefly is harnessing increased data and NVIDIA L40S GPU acceleration to power next-generation EEG/ERP processing, enabling new AI-driven biomarker discovery capabilities –
- Milestone supports Firefly’s goal of building and launching the world’s first EEG/ERP-based foundation model of the human brain -
KENMORE, N.Y., April 13, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announce the achievement of a major operational and commercial milestone: over 200,000 EEG/ERP (human brain function) scans.
Through its acquisition of Evoke Neuroscience, Inc. in May 2025, combined with the successful execution of its key internal growth initiatives, Firefly has now driven
“Surpassing this important milestone opens the door to us potentially making additional new breakthroughs in cognitive brain biomarker discovery, building upon those we’ve already recently made for differential diagnosis of ADHD, objective measurement of SCD/MCI/Dementia in Alzheimer's patients, and cognitive assessment of brain age,” commented Firefly’s Chief Executive Officer, Greg Lipschitz. “In so doing, we also believe we are now much closer to fulfilling our goal of building and launching the world’s first EEG/ERP-based foundation model of the human brain.”
About Firefly
Firefly Neuroscience, Inc. (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company advancing precision neuroscience, applying AI and large-scale electrophysiological data to give clinicians a more complete, objective picture of how an individual patient's brain is functioning. Firefly’s proprietary database now consists of over 200,000 EEG/ERP brain scans, making it the world’s largest known standardized EEG/ERP repository. Firefly’s EEG-based, AI-driven, and FDA-510(k)-cleared brain analytics technology has the potential to revolutionize diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD.
Please visit www.fireflyneuro.com for more information.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly’s management team’s expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Investor & Media Contact
Stephen Kilmer
(646) 274-3580
stephen.kilmer@fireflyneuro.com
